SK Plasma will exclusively distribute Janssen’s Velcade
By Nho, Byung Chul | translator Alice Kang
24.12.17 05:09:35
가나다라
0
Company signs an exclusive supply agreement with Janssen Korea for Velcade’s as a treatment for multiple myeloma and mantle cell lymphoma.
The companies expand their partnership into hemato-oncology following their signing of an agreement for Dacogen Inj
▲(From the left) Seungjoo Kim, CEO of SK Plasma, Christian Rodseth, Managing Director of Janssen Korea)
SK Plasma, which specializes in plasma derivatives, has secured an additional rare disease treatment for its portfolio.
SK Plasma (CEO: Seungjoo Kim) announced on the 16th that it had signed an exclusive domestic distribution agreement for the multiple myeloma and mantle cell lymphoma treatment Velcade inj (bortezomib triple complex) with Jassen Korea, Johnson & Johnson’s pharmaceutical division.
Under the agreement, Janssen will manufacture and supply Velcade Inj, and SK Plasma will be responsible for its distribution and marketing in Korea.
With this agreement, SK Plasma now owns a portfolio of leading blood cancer treatments, including Dacogen (myelodysplastic
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)